🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Dr. Agarwal's Eye Hospital Limited DRAGARWQ NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.dragarwal.com
Company Profile ↓
₹5,010.50
+4.65% 1Y
Mkt Cap₹2,421.49 Cr
P/E31.54
P/B7.27
52W High₹5,422.50
52W Low₹4,787.85
Book Value₹716.48
EPS (TTM)₹158.87

Company Overview

Dr. Agarwal's Eye Hospital Limited engages in the provision of eye care and related services in India, Ghana, Uganda, Kenya, Madagascar, Tanzania, Rwanda, Zambia, Mozambique, and Mauritius. The company, through its hospitals, offers services in the areas of cataract, glaucoma, laser correction, cornea and refractive, retina, squint, corneal ulcer, fungal keratitis, diabetic retinopathy, retinal detachment, nystagmus, ptosis, conjunctivitis, retinopathy prematurity, macular hole and edema, cornea transplantation, behcets, computer vision syndrome, hypertensive retinopathy, black fungus, traumatic cataract, keratoconus, uveitis, pterygium, blepharitis, posterior subcapsular cataract, pinhole pupilloplasty, rosette cataract, and congenital glaucoma. It also operates opticals and pharmacies and is engaged in the sale of optical frames, contact lenses, accessories, and pharmaceutical products. Dr. Agarwal's Eye Hospital Limited was founded in 1957 and is based in Chennai, India. Dr. Agarwal's Eye Hospital Limited operates as a subsidiary of Dr. Agarwal's Health Care Limited.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 20.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 15.0%.

Consistent Profit Growth

Net profit has compounded at 23.8% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 20.8% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 31.5, below the sector median of 36.4.

Healthy Margins

Maintains a net profit margin of 15.3%.

Recent Developments

  • Mar 2026 Revenue of ₹470.00 Cr (+18.3% YoY); net profit ₹70.10 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +22.3%, earnings +31.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR 20.8%, profit CAGR 23.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:20.78%
1 Year:22.30%

Compounded Profit Growth

5 Years:23.83%
1 Year:31.80%

Stock Price Performance

1 Year:+4.65%
6 Months:+4.65%
3 Months:-0.04%
1 Month:-6.72%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 35% of range
₹4,787.85 ₹5,422.50
Trend Signals
  • Price vs 50-DMABelow
  • RSI (14)35.55 · Neutral
Price Performance
1M-6.72%
3M-0.04%
6M+4.65%
1Y+4.65%
Valuation vs Sector

P/E of 31.54 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 20.2%.
  • Compounding revenue at 20.8% over 5 years.
  • Profit CAGR of 23.8% over 5 years.
  • Generates positive free cash flow.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
31.54
Industry PE
36.43
Forward P/E est.
23.93
PEG Ratio
-
Book Value
₹716.48
Price to Book
7.27
P/S
5.55
EV/EBITDA
17.59
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
20.78%
Profit 5Y
23.83%
Revenue (YoY)
22.30%
Earnings (YoY)
31.80%

Profitability & Returns

ROCE
15.05%
ROE
20.24%
ROA
9.15%
Profit Margin
15.34%
Op Margin
22.22%
Gross Margin
46.04%
EPS (Latest Qtr)
₹-
EPS (TTM)
₹158.87

Balance Sheet & Liquidity

Debt/Equity
0.94
Quick Ratio
1.10
Current Ratio
1.23
Debt
₹326.13 Cr
Total Assets
₹766.46 Cr
Current Assets
₹136.54 Cr
Working Capital
₹25.16 Cr

Ownership

Promoter Holding
82.33%
Chg in Prom Hold
-0.06%
FII / Inst Holding
1.79%
Chg in FII Hold
0.04%

Financial Snapshot

Enterprise Value
₹2,421.49 Cr
Total Revenue (TTM)
₹496.92 Cr
EBITDA
₹156.24 Cr
Free Cash Flow
₹46.75 Cr
Operating Cash Flow
₹145.14 Cr
Shares Outstanding
₹48.33 L
Gross Margin
46.04%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 DRAGARWQ Dr. Agarwal's Eye Hospital Limited NSEPHARMA 5,010.50 31.54 ₹2,421.49 Cr 0.00% 15.05% 20.24% 20.78% 23.83%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue 95.11 Cr99.83 Cr116.92 Cr116.22 Cr120.01 Cr
Cost of Revenue 22.07 Cr21.61 Cr26.14 Cr25.46 Cr24.97 Cr
Gross Profit 73.04 Cr78.22 Cr90.78 Cr90.76 Cr95.04 Cr
Operating Expenses 36.54 Cr56.83 Cr42.05 Cr68.05 Cr73.40 Cr
Operating Income 15.60 Cr21.39 Cr26.55 Cr22.71 Cr21.64 Cr
EBITDA 27.93 Cr31.09 Cr37.93 Cr37.14 Cr35.31 Cr
Interest Expense 3.85 Cr2.89 Cr4.16 Cr2.03 Cr1.96 Cr
Pretax Income 14.06 Cr18.00 Cr23.19 Cr23.45 Cr21.26 Cr
Tax Provision 3.66 Cr2.61 Cr5.93 Cr6.17 Cr5.01 Cr
Net Income 10.40 Cr15.99 Cr17.26 Cr17.28 Cr16.24 Cr
Diluted EPS -----

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -266.73 Cr316.54 Cr397.15 Cr470.00 Cr
Cost of Revenue -60.96 Cr70.55 Cr89.62 Cr101.46 Cr
Gross Profit -205.77 Cr245.99 Cr307.53 Cr368.54 Cr
Operating Expenses -149.30 Cr179.97 Cr228.48 Cr269.94 Cr
Operating Income -56.47 Cr66.02 Cr79.05 Cr98.60 Cr
EBITDA -76.38 Cr95.96 Cr123.59 Cr151.33 Cr
Interest Expense -6.80 Cr7.10 Cr13.44 Cr11.88 Cr
Pretax Income -49.40 Cr62.25 Cr70.70 Cr93.61 Cr
Tax Provision -12.48 Cr15.89 Cr16.05 Cr23.51 Cr
Net Income -36.92 Cr46.36 Cr54.65 Cr70.10 Cr
Diluted EPS -----

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -389.94 Cr495.76 Cr613.32 Cr766.46 Cr
Current Assets -46.54 Cr59.83 Cr55.94 Cr136.54 Cr
Cash & Equivalents -27.38 Cr32.88 Cr11.16 Cr6.63 Cr
Inventory -6.00 Cr9.75 Cr13.40 Cr14.10 Cr
Receivables -10.11 Cr12.93 Cr13.97 Cr18.71 Cr
Total Liabilities -276.60 Cr338.61 Cr403.71 Cr420.16 Cr
Current Liabilities -55.08 Cr80.77 Cr86.98 Cr111.38 Cr
Long Term Debt -35.77 Cr44.46 Cr81.77 Cr67.14 Cr
Total Debt -232.47 Cr268.02 Cr333.16 Cr326.13 Cr
Total Equity -113.34 Cr157.15 Cr209.61 Cr346.30 Cr
Shares Outstanding -47.00 L47.00 L47.00 L48.33 L

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -69.62 Cr89.77 Cr93.56 Cr145.14 Cr
Investing Cash Flow --70.61 Cr-70.04 Cr-132.78 Cr-173.53 Cr
Financing Cash Flow -26.00 L-14.23 Cr16.58 Cr24.78 Cr
Capital Expenditure --70.34 Cr-71.32 Cr-102.86 Cr-98.39 Cr
Free Cash Flow --72.00 L18.45 Cr-9.30 Cr46.75 Cr
Net Change in Cash --73.00 L5.50 Cr-22.64 Cr-3.61 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -77.1%77.7%77.4%78.4%
Operating Margin % -21.2%20.9%19.9%21.0%
Net Margin % -13.8%14.6%13.8%14.9%
ROE % -32.6%29.5%26.1%20.2%
ROCE % -16.9%15.9%15.0%15.1%

Shareholding Pattern

Insiders
82.33%
Institutions
1.79%
Public Float
10.15%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DRAGARWQ

Google News Sat, 17 Oct 2026

Dr. Agarwal's Eye Hospital Limited (DRAGARWQ.NS) latest stock news and headlines - Yahoo Finance UK

<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTFBmeld2dkFabUkxTUdDc1NTSGd0Y2FHVjJWa1JHSmcyekhteWZhTmNEX2Zsd2NuRW9Rd3N1NmtBT1NDSEt2dDhZWnV5RE5mdjdxS1RSM21zSXNqY0g3TkxlRDF3?oc=5" target="_blank">Dr. Agarwal's Eye Hospital Limited …

Google News Sat, 17 Oct 2026

Dr. Agarwal's Eye Hospital Limited (DRAGARWQ.NS) interactive stock chart - Yahoo Finance UK

<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTE1aZkxMb2R1V0phLXZzLV9rWEhTWnlNNkkyQW5rNFJQbXNkMzZaNXN3eXZTaXd1LUVWYjRIcVJleGFlYU5lLTlTVC1IbFc3V0FzR0R2dVgydGVRMTdyTmhScWZXUQ?oc=5" target="_blank">Dr. Agarwal's Eye Hospital Limite…

Google News Mon, 20 Apr 2026

DRAGARWQ Stock Price and Chart — NSE:DRAGARWQ - TradingView

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE9qendJSS15Q1d5Y1VWYjJocTRYR1MtcHB5cVRsYzBIQ1lXRHpVbGltOU56S0lfNTEzbjllVTA5VmV3RU9rRVlHSFNpQTlfcUtTRmktTElhUFZZNzc3REE?oc=5" target="_blank">DRAGARWQ Stock Price and Chart — NSE:DRA…

Google News Sat, 17 Oct 2026

Dr. Agarwal's Eye Hospital Limited (DRAGARWQ.NS) stock price, news, quote and history - Yahoo Finance UK

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE9fd2Y3bEFyZC1VdXBDcFNzazFLLUtGRzNKX3VjeWlyYXNfd0dfV3U5TExhdlN0RUR5bzNlY0Jvc2NPYUlhRkRVWkFON1NjQXMxYWtGdTdDN05sd00?oc=5" target="_blank">Dr. Agarwal's Eye Hospital Limited (DRAGARWQ…

Google News Sat, 17 Oct 2026

Dr. Agarwal's Eye Hospital Limited (DRAGARWQ.NS) stock major holders - Yahoo Finance UK

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5MN3RnWUJ5VlpuYW1BckNhWm4xN0ViTlc4aThONG9DMHpERTBiUFJJZTA2bGRHallHS0Fua0JEVU14eDdHaFdQXzY5ZzAtM2pJNHplUVdaUWhQXzJKdXVCTDN4Qmhkdw?oc=5" target="_blank">Dr. Agarwal's Eye Hospital Li…

Google News Wed, 07 Oct 2026

Dr Agarwals Eye Hospital (DRAGARWQ.NS) Eases 0.48% to ₹5,170 as Traders Eye the ₹4,911–₹5,428 Range - Negative Gamma - https://www.siam.in/

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQdm9qdFhIS0tYNEdELTIxNFdBbVRnNU92SVl0X3ZFLUJpUDY4U3dES3VqeVNWbHlyczhTWlhoX0FINnNOS3hLZHpJN2p1YzJYZmR1SkFYVVFoTUljTmhTU09BcTJrNy1ycmpzcEpvNzg4eEhDaTFJUlJZU0taeVdjN1FvMEt2Zmp2ZmF2Y2…

DRAGARWQ — Frequently Asked Questions

What is the current share price of Dr. Agarwal's Eye Hospital Limited (DRAGARWQ)?

As of 2026-10-23 04:58 IST, Dr. Agarwal's Eye Hospital Limited (DRAGARWQ) trades at ₹5,010.50 on NSE. Its 52-week range is ₹4,787.85 to ₹5,422.50.

What is the market capitalisation of DRAGARWQ?

Dr. Agarwal's Eye Hospital Limited (DRAGARWQ) has a market capitalisation of ₹2,421.49 Cr on NSE.

What is the P/E ratio of DRAGARWQ?

DRAGARWQ trades at a trailing price-to-earnings (P/E) ratio of 31.54. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 7.27.

What is the return on equity (ROE) of DRAGARWQ?

DRAGARWQ has a return on equity (ROE) of 20.24%. Its return on capital employed (ROCE) is 15.05%.

Is DRAGARWQ a good stock to buy?

This page provides a data-driven analysis of Dr. Agarwal's Eye Hospital Limited (DRAGARWQ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space